HLF

Rating neutralAI MemoPost-earnings T+3

Herbalife

As of 2026-08-08/Post-earnings T+3/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-08 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Q2 2026 earnings beat with mixed guidance revision • 2026-08-05

Base target: $13 / p=55% prob

Biggest risk

Reported EBITDA guidance was narrowed lower because of FX, gross margin declined year over year, and the GAAP result included a large debt-extinguishment loss. Bioniq and platform initiatives still require execution proof. No post-print analyst target, rating, or estimate revisions were verified.

Invalidation

Break below $10 or thesis failure.

What would change my mind?

Four consecutive quarters of net-sales growth, Q2 constant-currency execution above guidance, personalized-nutrition launches, and cash generation support a constructive medium-term case.

Research note

Recommendation

neutral

Confidence

medium

As of

2026-08-08

Base target

$13

p=55%

Bull target

$15

p=20%

Bear target

$10

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Bioniq and personalized-nutrition rollout
Four consecutive quarters of net-sales growth, Q2 constant-currency execution above guidance, personalized-nutrition launches, and cash generation support a constructive medium-term case.
The stored analyst target median is $18.33 versus the $11.51 anchor price, implying substantial headline upside, but the analyst count and target dates are unavailable.

BearKey bullets

CFO retirement and succession at year-end could add transition risk.
Demand durability and distributor engagement remain insufficiently evidenced beyond four quarters of growth.
Execution risk around Bioniq, Pro2col, and at-home diagnostic initiatives.

WatchKey bullets

Q2 2026 earnings beat with mixed guidance revision

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $13 (p=55%)

Target spread vs base: +20% / -24%

Scenario probabilities

Bull Target: $15 (p=20%)Base Target: $13 (p=55%)Bear Target: $10 (p=25%)

Commentary

The earnings print was operationally constructive but not a clean upgrade: growth and constant-currency execution beat guidance, while reported EBITDA guidance narrowed because of FX. The observed post-print price reaction was positive, with HLF at $12.35 on August 7 versus the $11.51 August 6 anchor, but no trusted source in the packet attributed the move specifically to earnings. Post-print analyst revisions, target changes, and estimate changes were unavailable, so this remains a tentative monitoring view.

As of 2026-08-08 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Four consecutive quarters of net-sales growth, Q2 constant-currency execution above guidance, personalized-nutrition launches, and cash generation support a constructive medium-term case.

Bear Case

Drivers

Scannable catalysts and supporting factors

Bioniq and personalized-nutrition rollout

Scenarios

Bull Target (Scenario probability)

$15 / p=20% prob

Base Target (Scenario probability)

$13 / p=55% prob

Bear Target (Scenario probability)

$10 / p=25% prob

Analysis 2026-08-08 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

68.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-08-05
Q2 2026 earnings beat with mixed guidance revision
Herbalife's August 5 SEC 8-K exhibit reported Q2 net sales of $1.3 billion, adjusted EBITDA of $166.6 million, and constant-currency results above guidance. Full-year adjusted EBITDA guidance narrowed for reported FX effects while constant-currency guidance increased. A bounded market-data check showed $12.35 on August 7, approximately 7.3% above the prior close. [#SEC-8K-2026-08-05] https://www.sec.gov/Archives/edgar/data/1180262/000121390026085702/ea030059301ex99-1.htm
Prob 100.00% • Move 7.30% • Priced-in 100.00%
EVENT2026-12-31
Cash generation and deleveraging follow-through
The company reported year-to-date operating cash flow of $146.7 million after the April refinancing. Further evidence of cash conversion and leverage reduction could support valuation, while refinancing benefits depend on sustained operating performance. [#SEC-8K-2026-05-06] [#SEC-8K-2026-08-05]
Prob 55.00% • Move 6.00% • Priced-in 60.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

Bioniq and personalized-nutrition rollout
2026-12-31
The company reported Bioniq GO launches across EMEA and North America, Pro2col platform enhancements, and an at-home blood-test beta. Sustained adoption could support growth, but execution and distributor uptake remain unproven. [#SEC-8K-2026-08-05]
Prob 45% • Move 8% • Priced-in 25%

Risks

CFO retirement and succession at year-end could add transition risk.
Demand durability and distributor engagement remain insufficiently evidenced beyond four quarters of growth.
Execution risk around Bioniq, Pro2col, and at-home diagnostic initiatives.
FX headwinds and a lower reported full-year adjusted EBITDA guidance range.
Gross-margin pressure from sales mix and other costs.
Recent insider open-market sales are a secondary caution signal, not evidence of operating deterioration. [#SEC-FORM4-2026-05-20]

Peers

Symbol	Summary
BRBR	Closest branded-nutrition comparison in the candidate set, useful for demand and margin framing, but its business model and balance sheet differ materially from Herbalife.
ENR	Adjacent household-products peer relevant for pricing, mix, leverage, and cash-flow comparison, but not a direct distributor-led analog.
EPC	Adjacent personal-care peer with some consumer and margin comparability, though operating overlap with Herbalife is limited.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-08

Loading AI feed…

Symbol

Summary

BRBR

Closest branded-nutrition comparison in the candidate set, useful for demand and margin framing, but its business model and balance sheet differ materially from Herbalife.

ENR

Adjacent household-products peer relevant for pricing, mix, leverage, and cash-flow comparison, but not a direct distributor-led analog.

EPC

Adjacent personal-care peer with some consumer and margin comparability, though operating overlap with Herbalife is limited.